{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:14:01Z","timestamp":1790788441793,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,11,14]],"date-time":"2016-11-14T00:00:00Z","timestamp":1479081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,11,14]],"date-time":"2016-11-14T00:00:00Z","timestamp":1479081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1038\/leu.2016.326","type":"journal-article","created":{"date-parts":[[2016,11,14]],"date-time":"2016-11-14T07:41:49Z","timestamp":1479109309000},"page":"1415-1422","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Inhibition of the Gab2\/PI3K\/mTOR signaling ameliorates myeloid malignancy caused by Ptpn11 (Shp2) gain-of-function mutations"],"prefix":"10.1038","volume":"31","author":[{"given":"W","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W-M","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R J","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M L","family":"Loh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K D","family":"Bunting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C-K","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,14]]},"reference":[{"key":"BFleu2016326_CR1","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S1097-2765(00)80415-3","volume":"5","author":"RA Birnbaum","year":"2000","unstructured":"Birnbaum RA, O'Marcaigh A, Wardak Z, Zhang YY, Dranoff G, Jacks T et al. Nf1 and Gmcsf interact in myeloid leukemogenesis. Mol Cell 2000; 5: 189\u2013195.","journal-title":"Mol Cell"},{"key":"BFleu2016326_CR2","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.V77.5.925.925","volume":"77","author":"PD Emanuel","year":"1991","unstructured":"Emanuel PD, Bates LJ, Castleberry RP, Gualtieri RJ, Zuckerman KS . Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood 1991; 77: 925\u2013929.","journal-title":"Blood"},{"key":"BFleu2016326_CR3","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1182\/blood-2014-03-300319","volume":"124","author":"TY Chang","year":"2014","unstructured":"Chang TY, Dvorak CC, Loh ML . Bedside to bench in juvenile myelomonocytic leukemia: insights into leukemogenesis from a rare pediatric leukemia. Blood 2014; 124: 2487\u20132497.","journal-title":"Blood"},{"key":"BFleu2016326_CR4","doi-asserted-by":"publisher","first-page":"308252","DOI":"10.1155\/2012\/308252","volume":"2012","author":"X Liu","year":"2012","unstructured":"Liu X, Sabnis H, Bunting KD, Qu CK . Molecular targets for the treatment of juvenile myelomonocytic leukemia. Adv Hematol 2012; 2012: 308252.","journal-title":"Adv Hematol"},{"key":"BFleu2016326_CR5","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1038\/leu.2008.162","volume":"22","author":"PD Emanuel","year":"2008","unstructured":"Emanuel PD . Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Leukemia 2008; 22: 1335\u20131342.","journal-title":"Leukemia"},{"key":"BFleu2016326_CR6","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1182\/blood-2003-09-3287","volume":"103","author":"ML Loh","year":"2004","unstructured":"Loh ML, Vattikuti S, Schubbert S, Reynolds MG, Carlson E, Lieuw KH et al. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood 2004; 103: 2325\u20132331.","journal-title":"Blood"},{"key":"BFleu2016326_CR7","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/ng1156","volume":"34","author":"M Tartaglia","year":"2003","unstructured":"Tartaglia M, Niemeyer CM, Fragale A, Song X, Buechner J, Jung A et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 2003; 34: 148\u2013150.","journal-title":"Nat Genet"},{"key":"BFleu2016326_CR8","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1182\/blood-2009-01-198416","volume":"114","author":"ML Loh","year":"2009","unstructured":"Loh ML, Sakai DS, Flotho C, Kang M, Fliegauf M, Archambeault S et al. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood 2009; 114: 1859\u20131863.","journal-title":"Blood"},{"key":"BFleu2016326_CR9","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1182\/blood-2009-06-226340","volume":"115","author":"H Muramatsu","year":"2010","unstructured":"Muramatsu H, Makishima H, Jankowska AM, Cazzolli H, O'Keefe C, Yoshida N et al. Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia. Blood 2010; 115: 1969\u20131975.","journal-title":"Blood"},{"key":"BFleu2016326_CR10","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1172\/JCI12758","volume":"108","author":"Y Zhang","year":"2001","unstructured":"Zhang Y, Taylor BR, Shannon K, Clapp DW . Quantitative effects of Nf1 inactivation on in vivo hematopoiesis. J Clin Invest 2001; 108: 709\u2013715.","journal-title":"J Clin Invest"},{"key":"BFleu2016326_CR11","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1172\/JCI20476","volume":"113","author":"IT Chan","year":"2004","unstructured":"Chan IT, Kutok JL, Williams IR, Cohen S, Kelly L, Shigematsu H et al. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest 2004; 113: 528\u2013538.","journal-title":"J Clin Invest"},{"key":"BFleu2016326_CR12","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1073\/pnas.0307203101","volume":"101","author":"BS Braun","year":"2004","unstructured":"Braun BS, Tuveson DA, Kong N, Le DT, Kogan SC, Rozmus J et al. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci USA 2004; 101: 597\u2013602.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2016326_CR13","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/nm1084","volume":"10","author":"T Araki","year":"2004","unstructured":"Araki T, Mohi MG, Ismat FA, Bronson RT, Williams IR, Kutok JL et al. Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat Med 2004; 10: 849\u2013857.","journal-title":"Nat Med"},{"key":"BFleu2016326_CR14","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1182\/blood-2004-10-4002","volume":"105","author":"RJ Chan","year":"2005","unstructured":"Chan RJ, Leedy MB, Munugalavadla V, Voorhorst CS, Li Y, Yu M et al. Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor. Blood 2005; 105: 3737\u20133742.","journal-title":"Blood"},{"key":"BFleu2016326_CR15","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1182\/blood-2008-10-182626","volume":"113","author":"G Chan","year":"2009","unstructured":"Chan G, Kalaitzidis D, Usenko T, Kutok JL, Yang W, Mohi MG et al. Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis. Blood 2009; 113: 4414\u20134424.","journal-title":"Blood"},{"key":"BFleu2016326_CR16","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1084\/jem.20110450","volume":"208","author":"D Xu","year":"2011","unstructured":"Xu D, Liu X, Yu WM, Meyerson HJ, Guo C, Gerson SL et al. Non-lineage\/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells. J Exp Med 2011; 208: 1977\u20131988.","journal-title":"J Exp Med"},{"key":"BFleu2016326_CR17","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ccr.2005.01.010","volume":"7","author":"MG Mohi","year":"2005","unstructured":"Mohi MG, Williams IR, Dearolf CR, Chan G, Kutok JL, Cohen S et al. Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell 2005; 7: 179\u2013191.","journal-title":"Cancer Cell"},{"key":"BFleu2016326_CR18","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/nature08240","volume":"460","author":"M Sanada","year":"2009","unstructured":"Sanada M, Suzuki T, Shih LY, Otsu M, Kato M, Yamazaki S et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature 2009; 460: 904\u2013908.","journal-title":"Nature"},{"key":"BFleu2016326_CR19","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10555-008-9126-y","volume":"27","author":"G Chan","year":"2008","unstructured":"Chan G, Kalaitzidis D, Neel BG . The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev 2008; 27: 179\u2013192.","journal-title":"Cancer Metastasis Rev"},{"key":"BFleu2016326_CR20","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/MOH.0b013e328353c6bf","volume":"19","author":"SC Nabinger","year":"2012","unstructured":"Nabinger SC, Chan RJ . Shp2 function in hematopoietic stem cell biology and leukemogenesis. Curr Opin Hematol 2012; 19: 273\u2013279.","journal-title":"Curr Opin Hematol"},{"key":"BFleu2016326_CR21","doi-asserted-by":"publisher","first-page":"4925","DOI":"10.2741\/3051","volume":"13","author":"D Xu","year":"2008","unstructured":"Xu D, Qu CK . Protein tyrosine phosphatases in the JAK\/STAT pathway. Front Biosci 2008; 13: 4925\u20134932.","journal-title":"Front Biosci"},{"key":"BFleu2016326_CR22","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/379277a0","volume":"379","author":"MJ Eck","year":"1996","unstructured":"Eck MJ, Pluskey S, Trub T, Harrison SC, Shoelson SE . Spatial constraints on the recognition of phosphoproteins by the tandem SH2 domains of the phosphatase SH-PTP2. Nature 1996; 379: 277\u2013280.","journal-title":"Nature"},{"key":"BFleu2016326_CR23","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S0092-8674(00)80938-1","volume":"92","author":"P Hof","year":"1998","unstructured":"Hof P, Pluskey S, Dhe-Paganon S, Eck MJ, Shoelson SE . Crystal structure of the tyrosine phosphatase SHP-2. Cell 1998; 92: 441\u2013450.","journal-title":"Cell"},{"key":"BFleu2016326_CR24","doi-asserted-by":"publisher","first-page":"30984","DOI":"10.1074\/jbc.M504699200","volume":"280","author":"H Keilhack","year":"2005","unstructured":"Keilhack H, David FS, McGregor M, Cantley LC, Neel BG . Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes. J Biol Chem 2005; 280: 30984\u201330993.","journal-title":"J Biol Chem"},{"key":"BFleu2016326_CR25","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1182\/blood-2013-10-535104","volume":"123","author":"CB Goodwin","year":"2014","unstructured":"Goodwin CB, Li XJ, Mali RS, Chan G, Kang M, Liu Z et al. PI3K p110delta uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML. Blood 2014; 123: 2838\u20132842.","journal-title":"Blood"},{"key":"BFleu2016326_CR26","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1172\/JCI69927","volume":"124","author":"K Gritsman","year":"2014","unstructured":"Gritsman K, Yuzugullu H, Von T, Yan H, Clayton L, Fritsch C et al. Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110alpha. J Clin Invest 2014; 124: 1794\u20131809.","journal-title":"J Clin Invest"},{"key":"BFleu2016326_CR27","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/370527a0","volume":"370","author":"P Rodriguez-Viciana","year":"1994","unstructured":"Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 1994; 370: 527\u2013532.","journal-title":"Nature"},{"key":"BFleu2016326_CR28","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/S0962-8924(03)00002-3","volume":"13","author":"H Gu","year":"2003","unstructured":"Gu H, Neel BG . The 'Gab' in signal transduction. Trends Cell Biol 2003; 13: 122\u2013130.","journal-title":"Trends Cell Biol"},{"key":"BFleu2016326_CR29","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1182\/blood.V99.5.1866","volume":"99","author":"K Nishida","year":"2002","unstructured":"Nishida K, Wang L, Morii E, Park SJ, Narimatsu M, Itoh S et al. Requirement of Gab2 for mast cell development and KitL\/c-Kit signaling. Blood 2002; 99: 1866\u20131869.","journal-title":"Blood"},{"key":"BFleu2016326_CR30","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1182\/blood-2006-11-060707","volume":"110","author":"Y Zhang","year":"2007","unstructured":"Zhang Y, Diaz-Flores E, Li G, Wang Z, Kang Z, Haviernikova E et al. Abnormal hematopoiesis in Gab2 mutant mice. Blood 2007; 110: 116\u2013124.","journal-title":"Blood"},{"key":"BFleu2016326_CR31","doi-asserted-by":"publisher","first-page":"5426","DOI":"10.1074\/jbc.M507622200","volume":"281","author":"WM Yu","year":"2006","unstructured":"Yu WM, Daino H, Chen J, Bunting KD, Qu CK . Effects of a Leukemia-associated Gain-of-Function Mutation of SHP-2 Phosphatase on Interleukin-3 Signaling. J Biol Chem 2006; 281: 5426\u20135434.","journal-title":"J Biol Chem"},{"key":"BFleu2016326_CR32","doi-asserted-by":"publisher","first-page":"5995","DOI":"10.1038\/sj.onc.1206846","volume":"22","author":"WM Yu","year":"2003","unstructured":"Yu WM, Hawley TS, Hawley RG, Qu CK . Catalytic-dependent and -independent roles of SHP-2 tyrosine Phosphatase in interleukin-3 signaling. Oncogene 2003; 22: 5995\u20136004.","journal-title":"Oncogene"},{"key":"BFleu2016326_CR33","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.leukres.2008.09.036","volume":"33","author":"YL Liu","year":"2009","unstructured":"Liu YL, Castleberry RP, Emanuel PD . PTEN deficiency is a common defect in juvenile myelomonocytic leukemia. Leuk Res 2009; 33: 671\u2013677.","journal-title":"Leuk Res"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2016326","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2016326.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/leu.2016.326","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/leu2016326.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:29:47Z","timestamp":1648744187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2016326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,14]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["BFleu2016326"],"URL":"https:\/\/doi.org\/10.1038\/leu.2016.326","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,14]]},"assertion":[{"value":"12 May 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}